These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 3530138)
1. [A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result]. Kimura I; Ohnoshi T; Masaoka T; Sampi K; Namba K Gan To Kagaku Ryoho; 1986 Sep; 13(9):2813-9. PubMed ID: 3530138 [TBL] [Abstract][Full Text] [Related]
2. [Mitoxantrone-containing combination chemotherapy in patients with non-Hodgkin's lymphoma]. Kimura I; Ohnoshi T; Masaoka T; Sampi K; Namba K Gan To Kagaku Ryoho; 1986 Oct; 13(10):3034-9. PubMed ID: 3532959 [TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
4. [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report]. Sampi K; Honda T; Hattori M Gan To Kagaku Ryoho; 1984 May; 11(5):1012-7. PubMed ID: 6202245 [TBL] [Abstract][Full Text] [Related]
5. A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study. Takagi T; Sampi K; Sawada U; Sakai C; Oguro M Int J Hematol; 1993 Jan; 57(1):67-71. PubMed ID: 8477064 [TBL] [Abstract][Full Text] [Related]
6. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy]. López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196 [TBL] [Abstract][Full Text] [Related]
7. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
8. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. Guglielmi C; Gherlinzoni F; Amadori S; Mazza P; Mantovani L; Lauria F; Martelli M; Zinzani PL; Greco V; Poletti G Haematologica; 1989; 74(6):563-9. PubMed ID: 2483401 [TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG). Santini G; Contu A; Porcellini A; Chisesi T; Coser P; Congiu AM; Morandi S; Manna A; Schintu GM; Quaini R Haematologica; 1991; 76(6):485-90. PubMed ID: 1820985 [TBL] [Abstract][Full Text] [Related]
10. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF; J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447 [TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (VEPA) for non-Hodgkin's lymphoma]. Saaki A; Yokomatsu Y; Kojima K; Yoshikawa T; Sannomiya Y; Tatsumi J; Hashimoto K; Park K; Kawarabayashi K; Yoshikawa C Gan To Kagaku Ryoho; 1986 Jan; 13(1):65-9. PubMed ID: 3753642 [TBL] [Abstract][Full Text] [Related]
12. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249 [TBL] [Abstract][Full Text] [Related]
13. [Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma]. Sampi K; Honda T; Hattori M; Takayama S Gan To Kagaku Ryoho; 1983 May; 10(5):1266-71. PubMed ID: 6191677 [TBL] [Abstract][Full Text] [Related]
14. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma]. Yuan ZY; Xu RH; He YJ; Guan ZZ Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996 [TBL] [Abstract][Full Text] [Related]
15. [Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment]. Niitsu H; Fukuda M; Fukuda S; Takatsu H; Nakayama Y; Hirokawa M; Mamiya S; Miura I; Takahashi F; Yoshida K Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2585-9. PubMed ID: 6594975 [TBL] [Abstract][Full Text] [Related]
16. The role of mitoxantrone in the treatment of indolent lymphomas. Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217 [TBL] [Abstract][Full Text] [Related]
17. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck. Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202 [TBL] [Abstract][Full Text] [Related]
18. [Salvage chemotherapy of non-Hodgkin's lymphoma with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP)]. Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):626-9. PubMed ID: 3827258 [TBL] [Abstract][Full Text] [Related]
19. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity. Brusamolino E; Bertini M; Guidi S; Vitolo U; Inverardi D; Merante S; Colombo A; Resegotti L; Bernasconi C; Ferrini PR Haematologica; 1988; 73(3):217-22. PubMed ID: 3139519 [No Abstract] [Full Text] [Related]
20. A randomized comparative study of cyclophosphamide, vincristine, doxorubicin, and prednisolone and cyclophosphamide, vincristine, mitoxantrone, and prednisolone regimens in the treatment of intermediate- and high-grade lymphoma with 8 years' follow-up. Bezwoda WR; Rastogi RB Semin Hematol; 1994 Apr; 31(2 Suppl 3):3. PubMed ID: 8073304 [No Abstract] [Full Text] [Related] [Next] [New Search]